Keryx Biophamaceutical, Inc. uses data discovered through the mapping of the human genome to generate drug candidates that target the regulation of protein kinases. Protein kinases play a key role in the way cells communicate.
Shares of Keryx Biopharmaceuticals (NASDAQ: KERX) are trading up 0.46% as of Mar 16, 10:19AM EDT, hitting 4.43. Keryx Biopharmaceuticals has a 52 week low of 2.42 and a 52 week high of 6.67. The companies last released earnings were -0.35 per share. were The company has a market cap of 265.52M and a price-to-earnings ratio of .